Approval · Notice of Compliance 27740 · 2022
COMBIVIR: Notice of Compliance 27740
Issued March 11, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27740
- Date
- March 11, 2022
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph with new information related to use in patients with moderate renal impairment, overdosage, transmission of HIV with antiretroviral therapy and lamivudine half-life. In addition, the Product Monograph was converted to 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COMBIVIR | Not yet assigned | — |
Medicinal ingredients
- ZIDOVUDINE 300 MG per TAB
- LAMIVUDINE 150 MG per TAB